<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003268</url>
  </required_header>
  <id_info>
    <org_study_id>TJUH-980407</org_study_id>
    <secondary_id>CDR0000066164</secondary_id>
    <secondary_id>ALZA-97-040-ii</secondary_id>
    <secondary_id>NCI-V98-1395</secondary_id>
    <nct_id>NCT00003268</nct_id>
  </id_info>
  <brief_title>Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Study of Cytosine Arabinoside, Idarubicin, and Amifostine as Induction Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
      Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of&#xD;
      chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of amifostine in treating patients with&#xD;
      newly diagnosed acute myeloid leukemia who are receiving idarubicin plus cytarabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether amifostine provides systemic protection against the nonhematologic&#xD;
           side effects of idarubicin (IDR) during induction therapy of acute myeloid leukemia&#xD;
           (AML), allowing the dose of idarubicin to be escalated.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of idarubicin when amifostine is used as a&#xD;
           chemotherapy protectant.&#xD;
&#xD;
        -  Determine the incidence and severity of dose limiting hypotension in patients receiving&#xD;
           amifostine and the ability to offset this side effect with vasoconstrictive agents.&#xD;
&#xD;
        -  Determine whether any additional side effects of amifostine are dose limiting in&#xD;
           patients with AML treated with IDR and cytarabine (ARA-C).&#xD;
&#xD;
        -  Monitor the frequency of alopecia, mucositis, diarrhea, and septicemia involving enteric&#xD;
           pathogens in these patients.&#xD;
&#xD;
        -  Determine the requirement for intravenous hyperalimentation in patients receiving&#xD;
           amifostine, IDR, and ARA-C.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of idarubicin (IDR).&#xD;
&#xD;
      Patients receive amifostine IV over 15 minutes, followed 15-30 minutes later by chemotherapy.&#xD;
      Idarubicin IV is administered over 15 minutes on days 1-3. Cytarabine is administered by&#xD;
      continuous infusion on days 1-7. Patients may receive 1 additional course of treatment, if&#xD;
      necessary.&#xD;
&#xD;
      Cohorts of 3-6 patients each are treated at each dose level of idarubicin. Dose escalation is&#xD;
      discontinued when 2 or more patients experience dose limiting toxicity.&#xD;
&#xD;
      Patients are followed at 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly diagnosed acute myeloid leukemia (AML)&#xD;
&#xD;
               -  M0-M2, M4-M7&#xD;
&#xD;
               -  Histologically proven by bone marrow aspirate and biopsy (requirement may be&#xD;
                  waived for patients with overt leukemia in the peripheral blood)&#xD;
&#xD;
               -  M3 (acute promyelocytic leukemia) patients excluded unless already treated with&#xD;
                  trans retinoic acid&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 50%&#xD;
&#xD;
          -  Must be able to stop taking antihypertensive medication 24 hours prior to cytarabine&#xD;
             administration&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No preexisting severe organ dysfunction&#xD;
&#xD;
          -  No history of underlying medical or psychiatric illness that may impair the patient's&#xD;
             ability to participate in the study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Effective contraception required of fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior cytotoxic therapy for AML&#xD;
&#xD;
          -  No prior amifostine&#xD;
&#xD;
          -  At least 1 month since chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 1 month since radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Flomenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kimmel Cancer Center of Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute monoblastic leukemia and acute monocytic leukemia (M5)</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

